R05CB03 - Carbocisteine |
Probably Not Porphyrinogenic |
PNP |
Rationale
Non-CYP metabolism. Absence of reported interactions with CYP-metabolised drugs indicate lack of capacity for CYP-induction or CYP-inhibition.
Chemical description
Modified amino acid, structurally related to cysteine.
Therapeutic characteristics
Mucolytic agent used to thin and loosen mucus in respiratory conditions. It is taken orally in doses up to 750 mg three times daily.
Published experience
No case reports found.
Ipnet drug reports
Uneventful use reported in 2 patients with acute porphyria.
Similar drugs
Explore alternative drugs in similar therapeutic classes
References
| # | Citation details | PubMed ID |
|---|---|---|
| 1. | Carbocysteine.
Brown DT. Drug Intell Clin Pharm. 1988; 22(7-8):603-8.
|
3046890 |
| Drug reference publications | ||
| 2. | DrugBank. Carbocisteine. Available from: https://go.drugbank.com/
Access Date: 2026-April-30 |
|
| 3. | Merative™ Micromedex® Drug Interaction Checking (electronic version). Ann Arbor, Michigan, USA: Merative. Available from: https://www.micromedexsolutions.com/
Access Date: 2026-April-30 |
|
| Drug interaction databases | ||
| 4. | Preston, C.L. (ed). Stockley’s Interaction Checker. London: Pharmaceutical Press. Available from: https://www.medicinescomplete.com/#/interactions/stockley
Access Date: 2026-April-30 |
|
| Summary of Product Characteristics | ||
| 5. | Summary of Product Characteristics (SmPC). Carbocisteine 375 mg Capsules. Flamingo Pharma (UK) Ltd. Date of revision of text: 24 January 2025. Available from: https://www.medicines.org.uk/emc/
|
|
Tradenames